10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Sunday, June 21, 2009

Wanbury Limited:-Managemnet speaks about future growth prospects and outlook

1)What is your outlook for the pharmaceutical industry in India?

ans)The pharmaceutical industry should do well in the coming years. In my opinion the domestic market should grow by 15% which is significant. IMS is of the opinion that it will continue to grow at 12-15%. Exports to the developed countries might see downside in keeping with the difficult phase these countries are passing through. However this would probably be an interim phase. Part of this could be offset by the buoyancy noticed in the emerging markets. It is the time to exercise corporate prudence and channelize ones efforts. And then of course there is a big opportunity for contract research and manufacturing services (CRAMS).

2)How well is Wanbury placed vis-à-vis its peers and what is its competitive edge in the industry?

ans)Wanbury’s competitive edge is its people. We have a passionate team, which has high vision and who truly THINK BIG. They believe in themselves and their abilities and set challenging benchmarks for individual and corporate performance on a continuous basis. As a company we foster entrepreneurial skills in our people. Marketing is our inherent strength in the domestic market and our focused, creative and professional approach has resulted in an ever increasing prescription base for our products .With new divisions being launched we will expand our doctor coverage and this should further boost prescriptions and thereby revenues.We are also working on developing specialized NDDS products .On the API front, we have 2 USFDA approved facilities and an office in Switzerland for CRAMS. Our R&D on the CRAMS front is strong. We manufacture cost-effective API’s and continuously work towardsoperational improvement. In terms of the Indian business, we have been ranked at 48th position by ORG-IMS. We are the fastest growing company in the top 100 companies for two years in a row. We got the "Best Brand Launch" by ORG-IMS for our Cpink and Rabiplus brands.

3)Please share with us your view on the current economic climate.

ans)The US market is likely to continue to grow negative about -2% for the next 4 yrs. Europe may also continue to grow negative about -2 to-3%. Where as, all the other markets would be positive and create more opportunities for cost effective companies with USFDA approvals. Indian market will not be affected by this and is expected to grow about 12-15%.

4)Do you have any further plans to expand you product basket?

ans)We are launching two new divisions in domestic formulations and would launch about 15 products in FY10 in all the five divisions. In API we would be launching 5 new products for CRAMS and 3 products for API’s for which the patent is expiring after 2014. This will be welcome additions to our revenues.

5)Could you give us an update on the company's expansion plans?

ans)We are increasing our manpower in formulations division by 300. These would be for the new divisions I spoke about earlier. Further in API, R&D, and Plants people and capacity would be increased for CRAMS.

6)It is learnt that Wanbury has set a target of Rs 10 billion revenue by 2011-12. Could you elaborate on this?

ans)We will do a business of Rs 10 billion by 2012. We intend to do business of Rs 3.4 billion with API and CRAMS, another Rs 3.4 billion in domestic formulations and about Rs 3.2 billion from Cantabria Pharma S.L. our Spanish subsidiary.

7)Would you like to convey any message to the shareholders and investors of the company?

ans)We are working towards fast growth in sales and profitability. We intend to increase our sales to Rs 10 billion and PAT to Rs 1.5 billion by 2012.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner